left
Hey There : )
right
company-image

Unlisted Shares

East India Pharmaceutical Works Limited Essentials

As of July 27, 2024, East India Pharmaceutical Works, Unlisted Shares are trading at ₹61.00 per share, with a 52-week high of ₹66 and 52-week low of ₹61. The minimun lot size is 3325 shares, and the shares are traded on NSDL and CDSL.

ISIN

INE254X01017

Face Value

₹ 10

Total Share

66,74,858

Total Income

₹ 233.35 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 40.72 Cr

Enterprise Value

₹ ****

Book Value

₹ 78.34

Intrinsic Value

₹ ****

Dividend Yield

2.05 %

Earnings Yield

4.15 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Small Cap

Cashflow - Operations

-₹ 3.11

Cashflow - Financing

3.86

East India Pharmaceutical Works Limited Growth

Compounded Sales Growth

1 Year

3 Year

6 Year

Compounded Profit Growth

1 Year

4 Year

6 Year

Return On Equity

2018

2021

2023

Highlights

image
  • First-of-their-kind Generic Drugs - East India Pharmaceutical Works developed several first-of-its-kind generic drugs in India, including the first indigenously developed antimalarial drug, the first generic version of metformin (anti-diabetic), and the first generic version of ramipril (anti-hypertensive). The company also has a strong pipeline of new products in development across various therapeutic areas. 
image
  • Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹201.6 Cr in FY22 to ₹233.3 Cr in FY23, indicating a growth rate of 15.7%. Over the past five years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 9.03% from FY18 to FY23.
image
  • Profitability -The company's profitability has consistently lagged behind industry standards. The EBIT margin, which stood at 3.6% in FY18, decreased to 2.9% in FY23, reflecting a Compound Annual Growth Rate (CAGR) of -4.65%. Although the net profit margin slightly increased from 0.4% in FY18 to 0.7% in FY23, the overall profitability was notably affected in FY23. This decline can be attributed to the rise in operating and other costs, impacting the overall profitability of the business.
image
  • Investment Thesis - When comparing East India Pharmaceutical Works to industry peers, the average price-to-earnings (P/E) ratio is around 32.17x. After incorporating the respective discounts, the share price is estimated to be in the range of ₹57 to ₹61. Despite positive signals related to revenue growth and profitability, the company seems to be slightly overvalued. Additionally, the Indian Pharmaceutical Industry is dominated by established giants serving a similar target market, limiting potential opportunities for East India Pharmaceutical Works to thrive.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

Quantity

Invest

, Min. Investment: ₹